A malaria vaccine jointly developed by the University of Oxford and Serum Institute of India (SII) has been recommended for use by the World Health Organization (WHO)’s Strategic Advisory Group of Experts and the Malaria Policy Advisory Group. The vaccine, known as R21/Matrix-M, is easily deployable and cost-effective, with the potential to manufacture hundreds of millions of doses. SII has already established production capacity for 100 million doses per annum, with plans to double it over the next two years. The WHO’s recommendation is crucial for Unicef and the Gavi vaccine alliance to procure the vaccine. This development marks a significant milestone in the fight against malaria, a disease responsible for half a million deaths annually.